Ates in HER2-negative Luminal BC that responds to induction F
Ates in HER2-negative Luminal BC that responds to induction F/G. Soon after eight months of F/G neoadjuvant therapy, a clinical advantage of 96 was attained with RS31 tumor diagnosis and…